readthroughSign in
Jul 17, 2026Weekly roundup4 fact check notes

Sanofi posts rilzabrutinib atopic dermatitis results; opens Phase 3 meningococcal vaccine trial in C

Sanofi released Phase 2 results for rilzabrutinib in atopic dermatitis and has a Phase 3 meningococcal conjugate vaccine study recruiting in Chinese infants and toddlers.

Sanofi had two registry updates in the period covered: posted results for a completed Phase 2 atopic dermatitis study and continued enrollment in a Phase 3 pediatric meningococcal vaccine trial in China.

  • The study enrolled 124 participants1 and its primary outcome was percent change from baseline to week 16 in Eczema Area and Severity Index (EASI) score.1
  • It plans to enroll 4568 participants2 and compares MenQuadfi (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) from Sanofi Pasteur2 against Menhycia (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) from CanSino Biologics.2

Fact check notes

  • ImpreciseSanofi posts rilzabrutinib atopic dermatitis results; opens Phase 3 meningococcal vaccine trial in CThe rilzabrutinib results claim is accurate, but 'opens' overstates the meningococcal trial's status—the study's actual start date (2026-08-22) and first posting (2026-07-17) predate this update period; the source shows it is 'recruiting' (ongoing), not newly opening. The entry's own body text correctly says 'continued enrollment,' contradicting the headline's 'opens.'
  • Checker's noteHeadline uses 'opens' for the meningococcal vaccine trial, but the study's actual start date (2026-08-22) and first posting (2026-07-17) occurred before this update period, and the trial is described as 'recruiting' (ongoing), not newly initiated—the entry's own body text correctly says 'continued enrollment,' which contradicts the headline wording.
  • Sentence removedRilzabrutinib, atopic dermatitis, Phase 2: This was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts to evaluate the efficacy and safety of rilzabrutinib in adult participants with moderate-to-severe atopic dermatitis and intolerance or inadequate response to topical corticosteroids.copied source wording
  • Sentence removedMenACYW conjugate vaccine, meningococcal infection prevention, Phase 3: The trial aims to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.